Demonstrated no mutations inside the c-Kit proto-oncogene or platelet-derived growth factor
Demonstrated no mutations within the c-Kit proto-oncogene or platelet-derived growth element receptor alpha (PDGFRA). Risk of recurrence was determined to be 90 . He started imatinib mesylate 400 mg each…